Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT01649466
- Locations
- 🇩🇪
Novartis Investigative Site, Würzburg, Germany
Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients
- Conditions
- Pharmacokinetics Study in de Novo Kidney Transplantation
- Interventions
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT01649427
- Locations
- 🇩🇪
Novartis Investigative Site, Koeln-Merheim, Germany
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01647789
- Locations
- 🇺🇸
UCSF Medical Center Dept of Oncology, San Francisco, California, United States
🇺🇸Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(2), San Antonio, Texas, United States
🇺🇸Seattle Cancer Care Alliance Dept. of SCCA, Seattle, Washington, United States
Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT01646671
- Locations
- 🇯🇵
Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
- Conditions
- Advanced Non Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01646125
- Locations
- 🇺🇸
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States
🇬🇧Novartis Investigative Site, Leicester, United Kingdom
🇺🇸Maryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01646684
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
- Conditions
- Pigmented Villonodular SynovitisPVNSGiant Cell Tumor of the Tendon SheathTenosynovial Giant Cell Tumor Localized or Diffused TypeGCCTSGCTS
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01643850
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
- Conditions
- Moderate to Severe Chronic Plaque-Type Psoriasis
- Interventions
- Drug: AIN457 300 mgDrug: AIN457 150 mgDrug: Placebo
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 675
- Registration Number
- NCT01640951
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
- Conditions
- Compensated Cirrhosis and Portal Hypertension
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT01640964
- Locations
- 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01637272
- Locations
- 🇺🇸
Virginia Endocrinology Research SC, Chesapeake, Virginia, United States
🇺🇸Montefiore Medical Center CLCZ696B2320, Bronx, New York, United States
🇳🇱Novartis Investigative Site, Utrecht, Netherlands